A Study to Investigate Safety and Efficacy of Osimertinib and Amivantamab in Participants With Non-small Cell Lung Cancer With Common Epidermal Growth Factor Receptor Mutations
← catalyst calendarNCT05801029 · readout in 408 d
Sponsored by AstraZeneca (industry) · AZN — their whole pipeline →. With Parexel.
Phase
Phase 2
Status
Active, not recruiting
Study type
Interventional
Design
Na · None · Treatment
Enrollment
60actual
Sites
29
Countries
Hong Kong, Malaysia, Singapore +3
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2023-07-18 | actual | When the study began enrolling |
| Primary completion | 2027-10-01 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2027-10-01 | estimated | The whole study's end, after follow-up |
| First posted | 2023-04-06 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-06-12 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Non-Small Cell Lung Cancer (NSCLC)
Interventions
- Drug: Osimertinib
- Drug: Amivantamab
Primary outcomes
what the primary-completion date above is the date OFNumber of participants with adverse events (AEs)
measured From screening (Day-28) to survival follow up (Approximately 52 months after the first participant is dosed)
Progression Free Survival (PFS)
measured From date of first dose of study intervention until radiological disease progression or death due to any cause (Approximately 52 months after the first participant is dosed)
Permalink · AZN's whole pipeline · Catalyst calendar · Every registered study · What changed